ClinicalTrials.gg
CompletedNCT03991169FeTCh-CKDUpdated Nov 18, 2026Results posted

Oral Iron in Children With Chronic Kidney Disease

A Phase 4 interventional study of Ferrous Sulfate in Chronic Kidney Insufficiency and Chronic Kidney Diseases, sponsored by Weill Medical College of Cornell University. Completed at 2 sites in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
596th of 819
29 · median 72
Started
2019
with 52 others
Phase 4
81 of 988
6 open now
Registered
600th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 596th largest by enrollment of the 819 interventional ones that give a count, is one of 53 that started in 2019, is one of 81 in phase 4, and was the 600th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs. no iron therapy arm for 3 months. The outcomes will include muscle strength, physical activity, and changes in eating behavior, which will be measured at enrollment and at the end of the study period.

03

Conditions studied

  • Chronic Kidney Insufficiency
  • Chronic Kidney Diseases

Keywords

  • Anemia
  • Iron
  • Children
  • Chronic kidney disease (CKD)
  • Appetite
  • Physical activity
  • Muscle strength
04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Age 1-21 years old (muscle strength will be assessed only in children >3 year old)
  • Estimated (GFR) \< 90 ml/min/1.73m2 by bedside Schwartz formula [height (cm) *0.413 / serum creatinine (mg/dL)]
  • (Hb) more or equal than 9.0 at the previous clinic visit
  • Hb less than 11.5 g/dL in children younger than 5 years Hb less than 12.0 g/dL in children 5-12 years Hb \<12.5 g/dL in children 12-15 yrs and females >15 yrs. Hb \<13.5 g/dL in males >15 years (all at the previous clinic visit)

Children with transferrin saturation ≤ 20% AND serum ferritin ≤ 100 ng/mL will be randomized into one of the arms

Key exclusion criteria:

  • Transferrin saturation \<5%
  • Serum ferritin \< 10 ng/mL
  • Iron therapy or erythrocyte stimulating agents (erythropoietin) therapy within 3 months prior to randomization
  • Blood transfusion within 4 months prior to enrollment
  • Children on hemodialysis
  • Rapidly deteriorating kidney function or expectation for transplantation or dialysis in less than 3 months
  • Pregnancy and breast-feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Oral Iron therapy

    Participant will receive oral iron therapy.

    Drug: Ferrous Sulfate

  • No intervention
    No oral iron therapy

    Participant will not receive oral iron therapy for 3 months.

Interventions

  • Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight \>43 kg.

    Also known as: iron sulfate

06

What researchers measure

Primary outcomes

  1. Change in Muscle Strength

    Hand-grip strength measured by a dynamometer.

    Time frame: Baseline to 3 months

  2. Change in Transferrin Saturation

    Transferrin saturation (TSAT) is the percentage of transferrin iron-binding sites occupied by iron and is calculated as serum iron divided by total iron-binding capacity, multiplied by 100. Change in TSAT was calculated as the 3-month value minus the baseline value; positive values indicate an increase in TSAT.

    Time frame: Baseline to 3 months

Secondary outcomes

  1. Change in Sedentary Time

    Sedentary time (in minutes per day) will be measured by actigraphy. Actigraph is a monitor that looks like a wristband or a watch that measures and records body movements throughout the day. Participating children will wear actigraphs for 7 days in the beginning and 7 days at the conclusion of the study.

    Time frame: Baseline to 3 months

  2. Change in Percent Skeletal Muscle Mass

    Skeletal muscle mass as a percentage of body weight was measured using bioelectrical impedance analysis. Change was calculated as the 3-month value minus the baseline value; positive values indicate an increase in the percentage of body weight represented by skeletal muscle mass.

    Time frame: Baseline to 3 months

  3. Change in Eating Behavior

    Eating behavior was assessed using the 35-item parent-reported Children's Eating Behaviour Questionnaire (CEBQ). Items are scored from 1 (Never) to 5 (Always), with applicable items reverse-scored. Each subscale score is the mean of its constituent items and ranges from 1 to 5. Higher scores indicate greater expression of the respective eating behavior: greater Enjoyment of Food, greater Slowness in Eating, greater Emotional Undereating, or greater Food Fussiness. In the context of this study, greater Enjoyment of Food was considered favorable; greater Emotional Undereating and Food Fussiness were considered unfavorable. Slowness in Eating reflects slower eating and does not have an inherently favorable or unfavorable direction. Change was calculated as the 3-month score minus the baseline score.

    Time frame: Baseline to 3 months

  4. Change in Quality of Life: PROMIS Physical Activity Score

    Physical activity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Physical Activity T-scores indicate greater physical activity. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.

    Time frame: Baseline to 3 months

  5. Change in Quality of Life: PROMIS Fatigue Score

    Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Fatigue T-scores indicate greater fatigue. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.

    Time frame: Baseline to 3 months

07

Results

Posted Nov 18, 2026

Participant flow

Participant flow — Overall Study
MilestoneOral Iron TherapyNo Oral Iron Therapy
Started1011
Completed1011
Not completed00

Outcome measures

PrimaryChange in Muscle Strength

Hand-grip strength measured by a dynamometer.

Time frame:
Baseline to 3 months
Reported as:
Mean · kg
Change in Muscle Strength
kgOral Iron TherapyNo Oral Iron Therapy
Change in Muscle Strength-0.125 ± 3.116-0.5625 ± 2.589
PrimaryChange in Transferrin Saturation

Transferrin saturation (TSAT) is the percentage of transferrin iron-binding sites occupied by iron and is calculated as serum iron divided by total iron-binding capacity, multiplied by 100. Change in TSAT was calculated as the 3-month value minus the baseline value; positive values indicate an increase in TSAT.

Time frame:
Baseline to 3 months
Reported as:
Mean · percent transferrin saturation
Change in Transferrin Saturation
percent transferrin saturationOral Iron TherapyNo Oral Iron Therapy
Change in Transferrin Saturation7.06 ± 8.43.4 ± 6.4
Statistical analysis
  • Oral Iron Therapy vs No Oral Iron Therapy · t-test, 2 sided · p = 0.31
SecondaryChange in Sedentary Time

Sedentary time (in minutes per day) will be measured by actigraphy. Actigraph is a monitor that looks like a wristband or a watch that measures and records body movements throughout the day. Participating children will wear actigraphs for 7 days in the beginning and 7 days at the conclusion of the study.

Time frame:
Baseline to 3 months

No measurements were reported for this outcome.

SecondaryChange in Percent Skeletal Muscle Mass

Skeletal muscle mass as a percentage of body weight was measured using bioelectrical impedance analysis. Change was calculated as the 3-month value minus the baseline value; positive values indicate an increase in the percentage of body weight represented by skeletal muscle mass.

Time frame:
Baseline to 3 months
Reported as:
Mean · percent skeletal muscle mass
Change in Percent Skeletal Muscle Mass
percent skeletal muscle massOral Iron TherapyNo Oral Iron Therapy
Change in Percent Skeletal Muscle Mass-2.63 ± 4.820.15 ± 5.29
SecondaryChange in Eating Behavior

Eating behavior was assessed using the 35-item parent-reported Children's Eating Behaviour Questionnaire (CEBQ). Items are scored from 1 (Never) to 5 (Always), with applicable items reverse-scored. Each subscale score is the mean of its constituent items and ranges from 1 to 5. Higher scores indicate greater expression of the respective eating behavior: greater Enjoyment of Food, greater Slowness in Eating, greater Emotional Undereating, or greater Food Fussiness. In the context of this study, greater Enjoyment of Food was considered favorable; greater Emotional Undereating and Food Fussiness were considered unfavorable. Slowness in Eating reflects slower eating and does not have an inherently favorable or unfavorable direction. Change was calculated as the 3-month score minus the baseline score.

Time frame:
Baseline to 3 months
Reported as:
Mean · Score on a scale
Change in Eating Behavior
Score on a scaleOral Iron TherapyNo Oral Iron Therapy
change in food enjoyment-0.3 ± 0.50.04 ± 0.5
change in eating slowness0.0 ± 0.30.1 ± 0.5
change in emotional under-eating0.4 ± 0.1-0.4 ± 0.7
change in food fussiness3.0 ± 0.73.1 ± 0.8
SecondaryChange in Quality of Life: PROMIS Physical Activity Score

Physical activity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Physical Activity T-scores indicate greater physical activity. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.

Time frame:
Baseline to 3 months
Reported as:
Mean · T-score points
Change in Quality of Life: PROMIS Physical Activity Score
T-score pointsOral Iron TherapyNo Oral Iron Therapy
Change in Quality of Life: PROMIS Physical Activity Score6.92 ± 5.605.075 ± 13.54
SecondaryChange in Quality of Life: PROMIS Fatigue Score

Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Fatigue T-scores indicate greater fatigue. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.

Time frame:
Baseline to 3 months
Reported as:
Mean · T-score points
Change in Quality of Life: PROMIS Fatigue Score
T-score pointsOral Iron TherapyNo Oral Iron Therapy
Change in Quality of Life: PROMIS Fatigue Score-4.62 ± 12.254.60 ± 9.71

Adverse events

Collected over From randomization until end of follow-up in 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Iron Therapy0/10 (0%)0/10 (0%)0/10 (0%)
No Oral Iron Therapy0/11 (0%)0/11 (0%)0/11 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Oral Iron TherapyNo Oral Iron TherapyTotal
Mean12.8 ± 6.213.1 ± 2.812.9 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)Oral Iron TherapyNo Oral Iron TherapyTotal
Female437
Male6814
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral Iron TherapyNo Oral Iron TherapyTotal
Black race156
Non-Black race9615
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jun 2023, 50 months.

Results were first posted in Nov 2026, 3 years 4 months after primary completion.

Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's 50 months is close to that.

Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2028 → Jun 2023 and completion Dec 2028 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 19, 2019
StartActual
Apr 19, 2019
Primary completionActual
Jun 28, 2023was Dec 2028
CompletionActual
Jun 28, 2023was Dec 2028
Results first posted
Nov 18, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Results
Results posted
posted Nov 18, 2026
Primary completion
Dec 31, 2028→Jun 28, 2023 (actual)
Nov 18, 2026
Study completion
Dec 31, 2028→Jun 28, 2023 (actual)
Nov 18, 2026
Enrollment
40 (estimated)→29 (actual)
Nov 18, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange in muscle strengthMuscle StrengthTime frame: 0 and 3 months → Baseline to 3 months
  • EditedChange in the percentage of transferrin saturation in the participants' bloodTransferrin SaturationTime frame: 0 and 3 months → Baseline to 3 months
Nov 18, 2026
Documents
Secondary outcomes
4 edited, 1 added
What changed in the outcomes
  • EditedChange in sedentary timeSedentary TimeTime frame: 0 and 3 months → Baseline to 3 months
  • EditedChange in the percent of skeletal muscle massPercent Skeletal Muscle MassTime frame: 0 and 3 months → Baseline to 3 months
  • EditedChange in eating behaviorEating BehaviorTime frame: 0 and 3 months → Baseline to 3 months
  • EditedChange in qualityQuality of lifeLife: PROMIS Physical Activity ScoreTime frame: 0 and 3 months → Baseline to 3 months
  • AddedChange in Quality of Life: PROMIS Fatigue ScoreTime frame: Baseline to 3 months
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Results posted
    Primary completion Dec 31, 2028→Jun 28, 2023 (now actual)
    Study completion Dec 31, 2028→Jun 28, 2023 (now actual)
    Enrollment 40 (estimated)→29 (actual)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in muscle strengthMuscle StrengthTime frame: 0 and 3 months → Baseline to 3 months
    • EditedChange in the percentage of transferrin saturation in the participants' bloodTransferrin SaturationTime frame: 0 and 3 months → Baseline to 3 months
    Secondary outcomes 4 edited, 1 added
    What changed in the outcomes
    • EditedChange in sedentary timeSedentary TimeTime frame: 0 and 3 months → Baseline to 3 months
    • EditedChange in the percent of skeletal muscle massPercent Skeletal Muscle MassTime frame: 0 and 3 months → Baseline to 3 months
    • EditedChange in eating behaviorEating BehaviorTime frame: 0 and 3 months → Baseline to 3 months
    • EditedChange in qualityQuality of lifeLife: PROMIS Physical Activity ScoreTime frame: 0 and 3 months → Baseline to 3 months
    • AddedChange in Quality of Life: PROMIS Fatigue ScoreTime frame: Baseline to 3 months
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03991169
Responsible party
Sponsor
First posted
Jun 19, 2019
Start date
Apr 19, 2019
Primary completion
Jun 28, 2023
Completion
Jun 28, 2023
Results posted
Nov 18, 2026
Last update
Nov 18, 2026

Study contacts

Oleh Akchurin, M.D.
principal investigator · Weill Cornell College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferrous sulfate

Start the discussion